# Phase 3 obesity trials recruiting: 115 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 115 trials in phase 3 for obesity that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 obesity trials: 115 rows for $5.75, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 13 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/obesity

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 115
- Recruiting or not yet: 115
- Read on: November 19, 2026

## Trials

The 25 newest of 115, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07943754 | Fighting Osteoporosis With Risedronate Co-Therapy During Incretin | Wake Forest University Health Sciences | Phase 3 | Not yet recruiting | Obesity | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943754) |
| November 12, 2026 | NCT07932925 | The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or... | Pfizer | Phase 3 | Not yet recruiting | Urinary Incontinence, Stress, Overweight and/or Obesity | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932925) |
| November 6, 2026 | NCT07922330 | A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These... | AstraZeneca | Phase 3 | Not yet recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922330) |
| November 5, 2026 | NCT07919678 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) | Pfizer | Phase 3 | Recruiting | Obesity, Overweight, Osteoarthritis of the Knee | 656 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919678) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 5, 2026 | NCT07918846 | A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Overweight, Obesity, Cardiovascular Disease | 8,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918846) |
| November 4, 2026 | NCT07915609 | A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Knee Osteoarthritis, Diabetes Melliuts, Type 2 | 756 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915609) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 15, 2026 | NCT07874633 | A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight | 432 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874633) |
| October 13, 2026 | NCT07871409 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871409) |
| October 8, 2026 | NCT07866066 | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Amgen | Phase 3 | Recruiting | Diabetes Mellitus, Type 2 | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07866066) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| October 2, 2026 | NCT07855900 | SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose... | Boehringer Ingelheim | Phase 3 | Recruiting | Obesity | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855900) |
| October 2, 2026 | NCT07854782 | Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854782) |
| September 30, 2026 | NCT07850063 | ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and... | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850063) |
| September 30, 2026 | NCT07850050 | SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have... | Boehringer Ingelheim | Phase 3 | Recruiting | Obesity | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850050) |
| September 29, 2026 | NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845500) |
| September 28, 2026 | NCT07844512 | Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing... | The First Hospital of Jilin University | Phase 3 | Recruiting | Pain Management, Overweight , Obesity, Respiration; Sleep Disorder | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844512) |
| September 28, 2026 | NCT07843498 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight | 3,900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843498) |
| September 28, 2026 | NCT07843485 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Type 2 Diabetes | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843485) |
| September 28, 2026 | NCT07843472 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established... | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Cardiovascular Disease | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843472) |
| September 23, 2026 | NCT07836270 | A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents | Hangzhou Sciwind Biosciences Co., Ltd. | Phase 3 | Not yet recruiting | Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836270) |
| September 18, 2026 | NCT07829198 | Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind... | Universidade do Porto | Phase 3 | Not yet recruiting | Obesity | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829198) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 16 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 16 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 10 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 7 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 6 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 5 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 4 |
| Hangzhou Sciwind Biosciences Co., Ltd. | 4 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 3 |
| [Gan & Lee Pharmaceuticals.](https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals) | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 2 |
| University of Colorado, Denver | 2 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 2 |
| Wake Forest University Health Sciences | 2 |
| Ascletis Pharma (China) Co., Limited | 2 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2 |
| [HK inno.N Corporation](https://specstream.ai/data/clinical-trials/company/hk-inno-n-corporation) | 1 |
| Universidade do Porto | 1 |
| Hospices Civils de Lyon | 1 |
| Kaiser Permanente | 1 |
| MindRank AI Ltd | 1 |
| Shahid Beheshti University of Medical Sciences | 1 |
| University of Alberta | 1 |
| Mount Sinai Hospital, Canada | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 65 |
| China | 48 |
| Spain | 31 |
| Germany | 29 |
| Japan | 29 |
| Canada | 28 |
| Poland | 26 |
| United Kingdom | 24 |
| Australia | 22 |
| Puerto Rico | 21 |
| South Korea | 20 |
| Taiwan | 19 |
| Argentina | 18 |
| Italy | 18 |
| Mexico | 18 |
| India | 18 |
| Brazil | 17 |
| Czechia | 16 |
| France | 16 |
| Denmark | 15 |
| Belgium | 14 |
| Turkey (Türkiye) | 13 |
| Bulgaria | 12 |
| Greece | 12 |
| Israel | 11 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Disability law firms in the United States](https://specstream.ai/data/businesses/disability-law-firms/united-states)
- [Surgery centers in the United States](https://specstream.ai/data/businesses/surgery-centers/united-states)
- [Home staging companies in the United States](https://specstream.ai/data/businesses/home-staging-companies/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [Obstetrics and gynecology practices in the United States](https://specstream.ai/data/businesses/obstetrics-and-gynecology-practices/united-states)
- [Computer wholesalers in the United States](https://specstream.ai/data/businesses/computer-wholesalers/united-states)
